Fintel reports that on August 9, 2023, EF Hutton reiterated coverage of Coya Therapeutics (NASDAQ:COYA) with a Buy recommendation.
Analyst Price Forecast Suggests 378.12% Upside
As of August 2, 2023, the average one-year price target for Coya Therapeutics is 18.36. The forecasts range from a low of 11.11 to a high of $29.40. The average price target represents an increase of 378.12% from its latest reported closing price of 3.84.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Coya Therapeutics is 0MM. The projected annual non-GAAP EPS is -1.35.
What is the Fund Sentiment?
There are 12 funds or institutions reporting positions in Coya Therapeutics. This is an increase of 6 owner(s) or 100.00% in the last quarter. Total shares owned by institutions increased in the last three months by 6.50% to 1,162K shares.
What are Other Shareholders Doing?
AIGH Capital Management holds 560K shares representing 5.63% ownership of the company. No change in the last quarter.
Greenlight Capital holds 393K shares representing 3.95% ownership of the company. In it's prior filing, the firm reported owning 392K shares, representing an increase of 0.05%. The firm decreased its portfolio allocation in COYA by 34.12% over the last quarter.
Worth Venture Partners holds 138K shares representing 1.38% ownership of the company. No change in the last quarter.
CM Management holds 60K shares representing 0.60% ownership of the company.
IWC - iShares Micro-Cap ETF holds 7K shares representing 0.07% ownership of the company.
Additional reading:
- CONDENSED BALANCE SHEETS
- AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT
- EXECUTIVE EMPLOYMENT AGREEMENT
- Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders
- Coya Therapeutics’ COYA 301 Increased Treg Function and Halted Cognitive Decline in an Open Label Study in Patients with Alzheimer’s Disease
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
